Stay updated on Nivolumab AVD in Early Unfavorable Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab AVD in Early Unfavorable Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab AVD in Early Unfavorable Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    No additions or deletions were detected on the page. The content remains focused on the Nivolumab and AVD trial details, eligibility criteria, and outcomes.
    Difference
    0.5%
    Check dated 2025-11-03T20:57:30.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    33 days ago
    Change Detected
    Summary
    Core content updated to reflect funding-related operating status and a new version release (v3.2.0), replacing the previous v3.1.0.
    Difference
    5%
    Check dated 2025-10-06T05:30:19.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.
    Difference
    0.1%
    Check dated 2025-09-29T03:03:42.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' element has been removed.
    Difference
    0.3%
    Check dated 2025-09-14T19:16:45.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.3%
    Check dated 2025-09-07T15:40:49.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated to include new drug information and a facility name, while removing several outdated terms and references related to lymphomas and neoplasms.
    Difference
    15%
    Check dated 2025-08-31T11:54:11.000Z thumbnail image

Stay in the know with updates to Nivolumab AVD in Early Unfavorable Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab AVD in Early Unfavorable Hodgkin Lymphoma Clinical Trial page.